The Effect of GVHD on Long-term Outcomes after Peripheral Blood Allogeneic Stem Cell Transplantation from an HLA-identical Sibling in Adult Acute Lymphocytic Leukemia: A Landmark Analysis Approach in Competing Risks
-
Arash Jalali
,
Kamran Alimoghaddam
,
Mahmood Mahmoudi
,
Kazem Mohammad
,
Seied Asadollah Mousavi
,
Babak Bahar
,
Mohammad Vaezi
,
Hojjat Zeraati
,
Mohammad Jahani
,
Ardeshir Ghavamzadeh
Abstract
Allogeneic Hematopoietic stem cell transplantation (HSCT) is the most effective therapy to prevent relapse in acute lymphocytic leukemia (ALL). This benefit is affected by non-relapse mortality (NRM) due to complications such as graft versus host disease (GVHD). A new approach in analyzing time-dependent covariates in competing risks is landmark analysis. So, the aim of this study is to evaluate the effect of acute and chronic GVHD on long-term outcomes, relapse and NRM, after allogeneic HSCT in adult ALL using landmark analysis. This study was conducted on 252 ALL patients who were allogeneic transplanted from an HLA-identical sibling with peripheral blood (PB) as the source of stem cell from 2004 to 2012 and were followed-up until 2013. In the first 100 days after transplant, a landmark analysis on days +10, +11, +12, +17, +24, and +31 was applied to assess the effect of acute GVHD on early relapse and NRM. Similarly, for patients alive and event-free at day +100 after transplant, a landmark analysis at time points day +101, months +4, +5, +6, +9, and +12 was applied to evaluate the effect of chronic GVHD on late relapse and NRM. Five-year LFS and OS were 35.0% (95% CI: 29.1, 42.2%) and 37.5% (95% CI: 31.3, 45.0%), respectively. Five-year cumulative incidence of relapse was 44.5% (95% CI: 37.9, 51.0%) while this was 20.4% (95% CI: 15.4, 26.0%) for NRM. The landmark analysis in the first 100 days after transplant showed that the grade III/IV of aGVHD has a lower risk of relapse but higher risk of NRM after adjustment for the EBMT risk score. For patients alive at day +100, cGVHD had no significant effect on relapse. Limited cGVHD had lower risk of NRM and after 6 month post-transplant the risk of NRM decreased and there were not important difference between the groups of cGVHD. Using advanced models enables us to estimate the effects more precisely and ultimately make inference more accurately.
Paulson K, Szwajcer D, Seftel MD. The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2011;44:197-203.
Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. New England Journal of Medicine. 1999;341:14-21.
Horowitz MM, Messerer D, Hoelzer D, Gale RP, Neiss A, Atkinson K, et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med. 1991;115:13-8.
Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Seminars in hematology: Elsevier; 2009. p. 64-75.
Horowitz MM, Gale RP, Sondel PM, Goldman J, Kersey J, Kolb H, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-62.
Kanda Y, Izutsu K, Hirai H, Sakamaki H, Iseki T, Kodera Y, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia. 2004;18:1013-9.
Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology. 2005;23:1993-2003.
Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Journal of Clinical Oncology. 2008; 26:577-84.
Klein JP, Rizzo J, Zhang M-J, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone marrow transplantation. 2001;28.
Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. Journal of Clinical Oncology. 1983;1:710-9.
Van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scandinavian Journal of Statistics. 2007;34:70-85.
Cortese G, Andersen PK. Competing Risks and Time‐Dependent Covariates. Biometrical Journal. 2010;52:138-58.
Nicolaie M, Houwelingen J, Witte T, Putter H. Dynamic prediction by landmarking in competing risks. Statistics in medicine. 2013;32:2031-47.
Ghavamzadeh A, Alimogaddam K, Jahani M, Mousavi S, Iravani M, Bahar B, et al. Hematopoietic stem cell transplantation in Iran: 1991 to 2008. Hematology/oncology and stem cell therapy. 2008;1:231-8.
Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, Iravani M, Bahar B, et al. Stem cell transplantation; Iranian experience. Arch Iran Med. 2009;12:69-72.
Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer. 2009;115:4715-26.
Gratwohl A. The EBMT risk score. Bone marrow transplantation. 2012;47:749-56.
Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R, et al. Clinical Manifestations of Graft-Versus-Host Disease in Human Recipients of Marrow From Hl-A-Matched Sibling Donor, S. Transplantation. 1974;18:295-304.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. The American journal of medicine. 1980;69:204-17.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999;94:496-509.
Putter H. dynpred: Companion package to "Dynamic Prediction in Clinical Survival Analysis". R package version 0.1.1 ed2011.
Therneau TM. A Package for Survival Analysis in S. 2.37-4 ed2013.
Gray B. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-6 ed2013.
R Core Team. R: A Language and Environment for Statistical Computing. 3.0.0 ed: R Foundation for Statistical Computing, Vienna, Austria.; 2013.
Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827-33.
Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. The New England journal of medicine. 2001;344:175-81.
Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000; 95:3702-9.
| Files | ||
| Issue | Vol 8, No 2 (2014) | |
| Section | Articles | |
| Keywords | ||
| Acute Lymphocytic Leukemia Competing Risks Graft versus Host Disease Landmark Analysis Peripheral Blood Stem Cell Transplantation Survival Analysis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
